# Roger Abounader

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/9132673/publications.pdf

Version: 2024-02-01

| | | | |
|---|---|---|---|
| 74<br>papers | 5,519<br>citations | 76326<br>40<br>h-index | 82547<br>72<br>g-index |
| 103<br>all docs | 103<br>docs citations | 103<br>times ranked | 7842<br>citing authors |

| # | Article | IF | Citations |
|---|---|---|---|
| 1 | microRNA-7 Inhibits the Epidermal Growth Factor Receptor and the Akt Pathway and Is Down-regulated in Glioblastoma. Cancer Research, 2008, 68, 3566-3572. | 0.9 | 705 |
| 2 | MicroRNA-34a Inhibits Glioblastoma Growth by Targeting Multiple Oncogenes. Cancer Research, 2009, 69, 7569-7576. | 0.9 | 566 |
| 3 | microRNA-34a is tumor suppressive in brain tumors and glioma stem cells. Cell Cycle, 2010, 9, 1031-1036. | 2.6 | 289 |
| 4 | Scatter factor/hepatocyte growth factor in brain tumor growth and angiogenesis. Neuro-Oncology, 2005, 7, 436-451. | 1.2 | 269 |
| 5 | The p53 Pathway in Glioblastoma. Cancers, 2018, 10, 297. | 3.7 | 232 |
| 6 | The Neuronal MicroRNA miR-326 Acts in a Feedback Loop with Notch and Has Therapeutic Potential against Brain Tumors. Journal of Neuroscience, 2009, 29, 15161-15168. | 3.6 | 211 |
| 7 | In vivo targeting of SF/HGF and câ€met expression via U1snRNA/ribozymes inhibits glioma growth and angiogenesis and promotes apoptosis. FASEB Journal, 2002, 16, 1-16. | 0.5 | 159 |
| 8 | Oncogenic effects of miR-10b in glioblastoma stem cells. Journal of Neuro-Oncology, 2013, 112, 153-163. | 2.9 | 151 |
| 9 | Targeting the c-Met Pathway Potentiates Glioblastoma Responses to Î³-Radiation. Clinical Cancer Research, 2005, 11, 4479-4486. | 7.0 | 117 |
| 10 | BIIE0246, a potent and highly selective non-peptide neuropeptide Y Y2 receptor antagonist. British Journal of Pharmacology, 2000, 129, 1075-1088. | 5.4 | 111 |
| 11 | microRNA-148a Is a Prognostic oncomiR That Targets MIG6 and BIM to Regulate EGFR and Apoptosis in Glioblastoma. Cancer Research, 2014, 74, 1541-1553. | 0.9 | 106 |
| 12 | The Scatter Factor/Hepatocyte Growth Factor: c-Met Pathway in Human Embryonal Central Nervous System Tumor Malignancy. Cancer Research, 2005, 65, 9355-9362. | 0.9 | 103 |
| 13 | Glycolytic glioma cells with active glycogen synthase are sensitive to PTEN and inhibitors of PI3K and gluconeogenesis. Laboratory Investigation, 2005, 85, 1457-1470. | 3.7 | 102 |
| 14 | Novel Anti-Apoptotic MicroRNAs 582-5p and 363 Promote Human Glioblastoma Stem Cell Survival via Direct Inhibition of Caspase 3, Caspase 9, and Bim. PLoS ONE, 2014, 9, e96239. | 2.5 | 95 |
| 15 | The role of microRNAs in glioma initiation and progression. Frontiers in Bioscience - Landmark, 2012, 17, 700. | 3.0 | 94 |
| 16 | Diacylglycerol Kinase Î± Is a Critical Signaling Node and Novel Therapeutic Target in Glioblastoma and Other Cancers. Cancer Discovery, 2013, 3, 782-797. | 9.4 | 93 |
| 17 | PTEN Has Tumor-Promoting Properties in the Setting of Gain-of-Function p53 Mutations. Cancer Research, 2008, 68, 1723-1731. | 0.9 | 92 |
| 18 | Transcription-Dependent Epidermal Growth Factor Receptor Activation by Hepatocyte Growth Factor. Molecular Cancer Research, 2008, 6, 139-150. | 3.4 | 85 |

| # | Article | IF | Citations |
|---|---|---|---|
| 19 | Characterization of neuropeptide Y (NPY) receptors in human cerebral arteries with selective agonists and the new Y<sub>1</sub> antagonist BIBP 3226. British Journal of Pharmacology, 1995, 116, 2245-2250. | 5.4 | 82 |
| 20 | MicroRNA-608 and MicroRNA-34a Regulate Chordoma Malignancy by Targeting EGFR, Bcl-xL and MET. PLoS ONE, 2014, 9, e91546. | 2.5 | 80 |
| 21 | Targetable T-type Calcium Channels Drive Glioblastoma. Cancer Research, 2017, 77, 3479-3490. | 0.9 | 79 |
| 22 | A New lncRNA, APTR, Associates with and Represses the CDKN1A/p21 Promoter by Recruiting Polycomb Proteins. PLoS ONE, 2014, 9, e95216. | 2.5 | 76 |
| 23 | Combined CDK4/6 and mTOR Inhibition Is Synergistic against Glioblastoma via Multiple Mechanisms. Clinical Cancer Research, 2017, 23, 6958-6968. | 7.0 | 74 |
| 24 | Signaling pathways in medulloblastoma. Journal of Cellular Physiology, 2008, 217, 577-583. | 4.1 | 72 |
| 25 | Expression of lncRNAs in Low-Grade Gliomas and Glioblastoma Multiforme: An In Silico Analysis. PLoS Medicine, 2016, 13, e1002192. | 8.4 | 71 |
| 26 | Functional and molecular interactions between the HGF/c-Met pathway and c-Myc in large-cell medulloblastoma. Laboratory Investigation, 2008, 88, 98-111. | 3.7 | 61 |
| 27 | Mitochondrial NIX Promotes Tumor Survival in the Hypoxic Niche of Glioblastoma. Cancer Research, 2019, 79, 5218-5232. | 0.9 | 57 |
| 28 | Down-regulation of c-Met inhibits growth in the liver of human colorectal carcinoma cells. Cancer Research, 2003, 63, 2990-6. | 0.9 | 55 |
| 29 | Role and Therapeutic Targeting of the HGF/MET Pathway in Glioblastoma. Cancers, 2017, 9, 87. | 3.7 | 53 |
| 30 | The roles of viruses in brain tumor initiation and oncomodulation. Journal of Neuro-Oncology, 2011, 105, 451-466. | 2.9 | 52 |
| 31 | Targeting the mesenchymal subtype in glioblastoma and other cancers via inhibition of diacylglycerol kinase alpha. Neuro-Oncology, 2018, 20, 192-202. | 1.2 | 52 |
| 32 | Regulation of c-Met-dependent gene expression by PTEN. Oncogene, 2004, 23, 9173-9182. | 5.9 | 51 |
| 33 | An Orally Bioavailable c-Met Kinase Inhibitor Potently Inhibits Brain Tumor Malignancy and Growth. Anti-Cancer Agents in Medicinal Chemistry, 2010, 10, 28-35. | 1.7 | 50 |
| 34 | Expression of Neuropeptide Y Receptors mRNA and Protein in Human Brain Vessels and Cerebromicrovascular Cells in Culture. Journal of Cerebral Blood Flow and Metabolism, 1999, 19, 155-163. | 4.3 | 49 |
| 35 | XL-184, a MET, VEGFR-2 and RET kinase inhibitor for the treatment of thyroid cancer, glioblastoma multiforme and NSCLC. IDrugs: the Investigational Drugs Journal, 2010, 13, 112-21. | 0.7 | 49 |
| 36 | Interactions between PTEN and the c-Met pathway in glioblastoma and implications for therapy. Molecular Cancer Therapeutics, 2009, 8, 376-385. | 4.1 | 46 |

| # | Article | IF | Citations |
|---|---|---|---|
| 37 | A Novel PTEN/Mutant p53/c-Myc/Bcl-XL Axis Mediates Context-Dependent Oncogenic Effects of PTEN with Implications for Cancer Prognosis and Therapy. Neoplasia, 2013, 15, 952-965. | 5.3 | 46 |
| 38 | Combined c-Met/Trk Inhibition Overcomes Resistance to CDK4/6 Inhibitors in Glioblastoma. Cancer Research, 2018, 78, 4360-4369. | 0.9 | 46 |
| 39 | microRNA-34a promotes DNA damage and mitotic catastrophe. Cell Cycle, 2013, 12, 3500-3511. | 2.6 | 45 |
| 40 | Targeting MET for glioma therapy. Neurosurgical Focus, 2014, 37, E10. | 2.3 | 45 |
| 41 | Interactions between PTEN and receptor tyrosine kinase pathways and their implications for glioma therapy. Expert Review of Anticancer Therapy, 2009, 9, 235-245. | 2.4 | 43 |
| 42 | A miR-297/hypoxia/DGK-Î± axis regulating glioblastoma survival. Neuro-Oncology, 2013, 15, 1652-1663. | 1.2 | 42 |
| 43 | Patterns of Capillary Plasma Perfusion in Brains of Conscious Rats During Normocapnia and Hypercapnia. Circulation Research, 1995, 76, 120-126. | 4.5 | 38 |
| 44 | Reduction of stromal fibroblast-induced mammary tumor growth, by retroviral ribozyme transgenes to hepatocyte growth factor/scatter factor and its receptor, c-MET. Clinical Cancer Research, 2003, 9, 4274-81. | 7.0 | 38 |
| 45 | CD44-independent hepatocyte growth factor/c-Met autocrine loop promotes malignant peripheral nerve sheath tumor cell invasion in vitro. Glia, 2004, 45, 297-306. | 4.9 | 36 |
| 46 | Discovery and Therapeutic Exploitation of Mechanisms of Resistance to MET Inhibitors in Glioblastoma. Clinical Cancer Research, 2019, 25, 663-673. | 7.0 | 35 |
| 47 | A cytoskeleton regulator AVIL drives tumorigenesis in glioblastoma. Nature Communications, 2020, 11, 3457. | 12.8 | 35 |
| 48 | MicroRNA-29a inhibits glioblastoma stem cells and tumor growth by regulating the PDGF pathway. Journal of Neuro-Oncology, 2019, 145, 23-34. | 2.9 | 33 |
| 49 | Combined PDGFR and HDAC Inhibition Overcomes PTEN Disruption in Chordoma. PLoS ONE, 2015, 10, e0134426. | 2.5 | 30 |
| 50 | Hepatocyte Growth Factor Sensitizes Brain Tumors to c-MET Kinase Inhibition. Clinical Cancer Research, 2013, 19, 1433-1444. | 7.0 | 29 |
| 51 | Regulatory factor X1 is a new tumor suppressive transcription factor that acts via direct downregulation of CD44 in glioblastoma. Neuro-Oncology, 2014, 16, 1078-1085. | 1.2 | 28 |
| 52 | Glioma Inhibition by HGF/NK2, an Antagonist of Scatter Factor/Hepatocyte Growth Factor. Biochemical and Biophysical Research Communications, 2000, 273, 287-293. | 2.1 | 23 |
| 53 | 370â€ƒMagnetic Resonance-Guided Focused Ultrasound Delivery of Polymeric Brain-Penetrating Nanoparticle MicroRNA Conjugates in Glioblastoma. Neurosurgery, 2016, 63, 210. | 1.1 | 22 |
| 54 | Myt1 and Myt1l transcription factors limit proliferation in GBM cells by repressing YAP1 expression. Biochimica Et Biophysica Acta - Gene Regulatory Mechanisms, 2018, 1861, 983-995. | 1.9 | 21 |

| # | Article | IF | Citations |
|---|---|---|---|
| 55 | HGF/MET Signaling in Malignant Brain Tumors. International Journal of Molecular Sciences, 2020, 21, 7546. | 4.1 | 21 |
| 56 | Cooperation between c-Met and Focal Adhesion Kinase Family Members in Medulloblastoma and Implications for Therapy. Molecular Cancer Therapeutics, 2012, 11, 288-297. | 4.1 | 20 |
| 57 | p53 and NF 1 loss plays distinct but complementary roles in glioma initiation and progression. Glia, 2018, 66, 999-1015. | 4.9 | 19 |
| 58 | Noncoding RNAs in Glioblastoma. , 0, , 95-130. | | 19 |
| 59 | The tumor-suppressive long noncoding RNA DRAIC inhibits protein translation and induces autophagy by activating AMPK. Journal of Cell Science, 2021, 134, . | 2.0 | 18 |
| 60 | Scatter factor/hepatocyte growth factor gene transfer increases rat bloodâ€“glioma barrier permeability. Brain Research, 1999, 833, 173-180. | 2.2 | 16 |
| 61 | Ethanol Extract of Securidaca longipedunculata Induces Apoptosis in Brain Tumor (U87) Cells. BioMed Research International, 2019, 2019, 1-5. | 1.9 | 11 |
| 62 | Insight into the role of microRNAs in brain tumors (Review). International Journal of Oncology, 2011, 40, 605-24. | 3.3 | 10 |
| 63 | MicroRNA 3928 Suppresses Glioblastoma through Downregulation of Several Oncogenes and Upregulation of p53. International Journal of Molecular Sciences, 2022, 23, 3930. | 4.1 | 8 |
| 64 | Design and Expression of Chimeric U1/Ribozyme Transgenes. , 2004, 252, 209-220. | | 7 |
| 65 | The p53â€“microRNA-34a axis regulates cellular entry receptors for tumor-associated human herpes viruses. Medical Hypotheses, 2013, 81, 62-67. | 1.5 | 7 |
| 66 | Activities of Some Medicinal Plants on the Proliferation and Invasion of Brain Tumor Cell Lines. Advances in Pharmacological and Pharmaceutical Sciences, 2020, 2020, 1-7. | 1.3 | 6 |
| 67 | MicroRNAs: Key Regulators in Lung Cancer. MicroRNA (Shariqah, United Arab Emirates), 2021, 10, 109-122. | 1.2 | 6 |
| 68 | Transcribed Ultraconserved Regions in Cancer. Cells, 2022, 11, 1684. | 4.1 | 6 |
| 69 | When tumor cells make blood vessels: implications for glioblastoma therapy. Future Oncology, 2011, 7, 841-843. | 2.4 | 5 |
| 70 | Gene expression in mouse muscle over time after nickel pellet implantation. Metallomics, 2020, 12, 528-538. | 2.4 | 5 |
| 71 | The blood-brain barrier limits the therapeutic efficacy of antibody-drug conjugates in glioblastoma. Neuro-Oncology, 2021, 23, 1993-1994. | 1.2 | 4 |
| 72 | A new practical and versatile mouse model of proneural glioblastoma. Neuro-Oncology, 2018, 20, 299-301. | 1.2 | 2 |

| # | Article | IF | Citations |
|---|---|---|---|
| 73 | A new class of radiosensitizers for glioblastoma. Oncotarget, 2021, 12, 1199-1200. | 1.8 | 0 |
| 74 | CSIG-01. IDENTIFICATION OF PATHOGENESIS-RELEVANT microRNAs IN BRAIN METASTASIS. Neuro-Oncology, 2020, 22, ii27-ii27. | 1.2 | 0 |